Technical Data
A3330-02F
ARF, p14 (p14ARF )
Description:
The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF.

Positive Control: BT549 or HeLa whole cell extracts

Applications:
Suitable for use in Immunofluorescence and Western Blot. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ul-20CBlue IceHuman Rabbit
Concentration:
Not determined
Immunogen:
A synthetic peptide to human p14ARF (C-terminal sequence).
Purity:
Purified by immunoaffinity chromatography.
Form
As reported
Specificity:
This antibody is specific for p14ARF. Species Crossreactivity: This antibody reacts with human p14ARF. Other species untested.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Newcomb, E.W., et al. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas. Human Pathology. 31(1): 115-9, 2000.
2. Taniguchi, T., et al. Expression of p16INK4a and p14ARF in hematological malignancies. Leukemia. 13(11): 1760-9, 1999.
3. Simon, M. et al. Functional evidence for a role of combined CDKN2A (p16-p14(ARF))/CDKN2A (p15) gene activation in malignant gliomas. Acta Neuropathol. 98(5): 444-52, 1999.
4. Herbert, B., et al. p16INK4a inactivation is not required to immortalize human mammary epithelial cells. Oncogene. 21:7897-7900, 2002.